Cargando…
Bell's palsy during rechallenge of immune checkpoint inhibitor
INTRODUCTION: The peripheral nervous system is one of the target organs of immune‐related adverse events. Peripheral facial nerve palsy, also called Bell's palsy, which is induced by immune checkpoint inhibitors, is quite rare, and its clinical features are not well known. CASE PRESENTATION: A...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9978074/ https://www.ncbi.nlm.nih.gov/pubmed/36875003 http://dx.doi.org/10.1002/iju5.12572 |
_version_ | 1784899433538781184 |
---|---|
author | Takemura, Kohji Yamanaka, Taro Hayashida, Michikata Kizawa, Rika Yamaguchi, Takeshi Tanabe, Yuko Sakaguchi, Kazushige Suyama, Koichi Urakami, Shinji Miura, Yuji |
author_facet | Takemura, Kohji Yamanaka, Taro Hayashida, Michikata Kizawa, Rika Yamaguchi, Takeshi Tanabe, Yuko Sakaguchi, Kazushige Suyama, Koichi Urakami, Shinji Miura, Yuji |
author_sort | Takemura, Kohji |
collection | PubMed |
description | INTRODUCTION: The peripheral nervous system is one of the target organs of immune‐related adverse events. Peripheral facial nerve palsy, also called Bell's palsy, which is induced by immune checkpoint inhibitors, is quite rare, and its clinical features are not well known. CASE PRESENTATION: A man with renal cell carcinoma who received rechallenging immune checkpoint inhibitor therapy developed unilateral facial palsy and was diagnosed with Bell's palsy. He did not have any severe immune‐related adverse events during his previous immune checkpoint inhibitor treatment. Corticosteroid therapy was immediately initiated, and his facial palsy symptoms promptly improved. CONCLUSION: Physicians should be aware that Bell's palsy can occur as an immune‐related adverse event. Additionally, careful observation is necessary during rechallenge with immune checkpoint inhibitors, even in patients who did not have previous immune‐related adverse events. |
format | Online Article Text |
id | pubmed-9978074 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-99780742023-03-03 Bell's palsy during rechallenge of immune checkpoint inhibitor Takemura, Kohji Yamanaka, Taro Hayashida, Michikata Kizawa, Rika Yamaguchi, Takeshi Tanabe, Yuko Sakaguchi, Kazushige Suyama, Koichi Urakami, Shinji Miura, Yuji IJU Case Rep Case Reports INTRODUCTION: The peripheral nervous system is one of the target organs of immune‐related adverse events. Peripheral facial nerve palsy, also called Bell's palsy, which is induced by immune checkpoint inhibitors, is quite rare, and its clinical features are not well known. CASE PRESENTATION: A man with renal cell carcinoma who received rechallenging immune checkpoint inhibitor therapy developed unilateral facial palsy and was diagnosed with Bell's palsy. He did not have any severe immune‐related adverse events during his previous immune checkpoint inhibitor treatment. Corticosteroid therapy was immediately initiated, and his facial palsy symptoms promptly improved. CONCLUSION: Physicians should be aware that Bell's palsy can occur as an immune‐related adverse event. Additionally, careful observation is necessary during rechallenge with immune checkpoint inhibitors, even in patients who did not have previous immune‐related adverse events. John Wiley and Sons Inc. 2023-01-16 /pmc/articles/PMC9978074/ /pubmed/36875003 http://dx.doi.org/10.1002/iju5.12572 Text en © 2023 The Authors. IJU Case Reports published by John Wiley & Sons Australia, Ltd on behalf of Japanese Urological Association. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Case Reports Takemura, Kohji Yamanaka, Taro Hayashida, Michikata Kizawa, Rika Yamaguchi, Takeshi Tanabe, Yuko Sakaguchi, Kazushige Suyama, Koichi Urakami, Shinji Miura, Yuji Bell's palsy during rechallenge of immune checkpoint inhibitor |
title | Bell's palsy during rechallenge of immune checkpoint inhibitor |
title_full | Bell's palsy during rechallenge of immune checkpoint inhibitor |
title_fullStr | Bell's palsy during rechallenge of immune checkpoint inhibitor |
title_full_unstemmed | Bell's palsy during rechallenge of immune checkpoint inhibitor |
title_short | Bell's palsy during rechallenge of immune checkpoint inhibitor |
title_sort | bell's palsy during rechallenge of immune checkpoint inhibitor |
topic | Case Reports |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9978074/ https://www.ncbi.nlm.nih.gov/pubmed/36875003 http://dx.doi.org/10.1002/iju5.12572 |
work_keys_str_mv | AT takemurakohji bellspalsyduringrechallengeofimmunecheckpointinhibitor AT yamanakataro bellspalsyduringrechallengeofimmunecheckpointinhibitor AT hayashidamichikata bellspalsyduringrechallengeofimmunecheckpointinhibitor AT kizawarika bellspalsyduringrechallengeofimmunecheckpointinhibitor AT yamaguchitakeshi bellspalsyduringrechallengeofimmunecheckpointinhibitor AT tanabeyuko bellspalsyduringrechallengeofimmunecheckpointinhibitor AT sakaguchikazushige bellspalsyduringrechallengeofimmunecheckpointinhibitor AT suyamakoichi bellspalsyduringrechallengeofimmunecheckpointinhibitor AT urakamishinji bellspalsyduringrechallengeofimmunecheckpointinhibitor AT miurayuji bellspalsyduringrechallengeofimmunecheckpointinhibitor |